Doulamis Ilias P, Tzani Aspasia, Kourek Christos, Kampaktsis Polydoros N, Inampudi Chakradhari, Kilic Ahmet, Briasoulis Alexandros
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts, USA.
Clin Transplant. 2022 Dec;36(12):e14804. doi: 10.1111/ctr.14804. Epub 2022 Sep 12.
Available literature indicates the possible detrimental effect of sex mismatching on mortality in patients undergoing heart transplantation. Our objective was to examine the role of sex and heart mass (predicted heart mass [PHM]) mismatch on mortality and graft rejection in patients undergoing heart transplantation in the US.
Data on adult patients who underwent heart transplantation between January 2015 and October 2021 were queried from the United Network of Organ Sharing (UNOS) registry. The main outcomes were all-cause mortality, 1-year all-cause mortality and treated acute rejection.
A total of 19 805 adult patients underwent heart transplant during the study period. 92.2% of the patients in the female graft to male group had a PHM mismatch <25%, while only 38.5% had such a mismatch in the male graft to female group. In male to male and female to female groups, 79% and 76% of the patients had a PHM mismatch <25% (p = .122). Proportion of PHM mismatch was similar throughout the study period. Unadjusted analysis showed that male recipients of female grafts had increased risk for all-cause mortality (hazard ratio [HR]: 1.13; 95% confidence intervals [CI]: 1.02, 1.27; p = .026) and 1-year mortality (HR: 1.26; 95% CI: 1.09, 1.45; p = .002) compared to male recipients of male grafts. Graft failure incidence was also higher (HR: 1.12; 95% CI: 1.01, 1.25; p = .041). However, all these associations were non- significant after risk factor adjustment.
Sex mismatching is associated with post-transplant mortality with transplantation of female donor grafts to male recipients demonstrating worse outcomes, although this association disappears after risk factor adjustment. Further research is required to elucidate the need for potential changes in clinical practice.
现有文献表明,性别不匹配可能对心脏移植患者的死亡率产生不利影响。我们的目的是研究性别和心脏质量(预测心脏质量[PHM])不匹配在美国心脏移植患者死亡率和移植排斥反应中的作用。
从器官共享联合网络(UNOS)登记处查询2015年1月至2021年10月期间接受心脏移植的成年患者的数据。主要结局为全因死亡率、1年全因死亡率和治疗的急性排斥反应。
在研究期间,共有19805名成年患者接受了心脏移植。女性供体移植给男性的患者中,92.2%的患者PHM不匹配<25%,而男性供体移植给女性的患者中只有38.5%有这种不匹配。在男性对男性和女性对女性组中,79%和76%的患者PHM不匹配<25%(p = 0.122)。在整个研究期间,PHM不匹配的比例相似。未经调整的分析显示,与接受男性供体移植的男性受者相比,接受女性供体移植的男性受者全因死亡率风险增加(风险比[HR]:1.13;95%置信区间[CI]:1.02,1.27;p = 0.026),1年死亡率风险增加(HR:1.26;95%CI:1.09,1.45;p = 0.002)。移植失败发生率也更高(HR:1.12;95%CI:1.01,1.25;p = 0.041)。然而,在进行风险因素调整后,所有这些关联均无统计学意义。
性别不匹配与移植后死亡率相关,女性供体移植给男性受者的移植结果较差,尽管在进行风险因素调整后这种关联消失。需要进一步研究以阐明临床实践中潜在改变的必要性。